Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/43580
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCaeyman, Aaron-
dc.contributor.authorVandekerckhove, Olivia-
dc.contributor.authorPat, Karin-
dc.contributor.authorWynants, Jokke-
dc.contributor.authorWeytjens, Karolien-
dc.contributor.authorde Wergifosse, Isabelle-
dc.contributor.authorCUPPENS, Kristof-
dc.date.accessioned2024-08-19T14:14:26Z-
dc.date.available2024-08-19T14:14:26Z-
dc.date.issued2023-
dc.date.submitted2024-08-19T11:04:14Z-
dc.identifier.citationCase reports in oncology, 16 (1) , p. 1095 -1099-
dc.identifier.urihttp://hdl.handle.net/1942/43580-
dc.description.abstractIn this report, we present a patient with metastatic non-small cell lung cancer who developed Sjogren's syndrome secondary to immune checkpoint inhibition. This patient had a typical clinical presentation as well as biochemical signature, developing only 18 months after the start of treatment with PD-1 inhibition (pembrolizumab).-
dc.language.isoen-
dc.publisherKARGER-
dc.rights2023 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.-
dc.subject.otherSjogren's syndrome: Sicca syndrome-
dc.subject.otherPembrolizum-
dc.subject.otherabImmune checkpoint inhibition-
dc.subject.otherNon-small cell lung carcinoma-
dc.subject.otherImmune-related adverse event-
dc.subject.otherCase report-
dc.titleSjogren's Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient-
dc.typeJournal Contribution-
dc.identifier.epage1099-
dc.identifier.issue1-
dc.identifier.spage1095-
dc.identifier.volume16-
local.format.pages5-
local.bibliographicCitation.jcatA1-
dc.description.notesCuppens, K (corresponding author), Jessa Hosp, Dept Resp Med & Thorac Oncol, Hasselt, Belgium.-
dc.description.notesKristof.cuppens@jessazh.be-
local.publisher.placeALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1159/000532098-
dc.identifier.pmid37900791-
dc.identifier.isi001203472100147-
dc.contributor.orcidCuppens, Kristof/0000-0002-8153-0008-
local.provider.typewosris-
local.description.affiliation[Caeyman, Aaron] Univ Hosp Leuven, Dept Internal Med, Leuven, Belgium.-
local.description.affiliation[Vandekerckhove, Olivia] Univ Hosp Leuven, Dept Resp Med, Leuven, Belgium.-
local.description.affiliation[Pat, Karin; Wynants, Jokke; Weytjens, Karolien; Cuppens, Kristof] Jessa Hosp, Dept Resp Med & Thorac Oncol, Hasselt, Belgium.-
local.description.affiliation[de Wergifosse, Isabelle] Jessa Hosp, Dept Rheumatol, Hasselt, Belgium.-
local.uhasselt.internationalno-
item.fullcitationCaeyman, Aaron; Vandekerckhove, Olivia; Pat, Karin; Wynants, Jokke; Weytjens, Karolien; de Wergifosse, Isabelle & CUPPENS, Kristof (2023) Sjogren's Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient. In: Case reports in oncology, 16 (1) , p. 1095 -1099.-
item.accessRightsOpen Access-
item.fulltextWith Fulltext-
item.contributorCaeyman, Aaron-
item.contributorVandekerckhove, Olivia-
item.contributorPat, Karin-
item.contributorWynants, Jokke-
item.contributorWeytjens, Karolien-
item.contributorde Wergifosse, Isabelle-
item.contributorCUPPENS, Kristof-
crisitem.journal.issn1662-6575-
crisitem.journal.eissn1662-6575-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient.pdfPublished version374.2 kBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

1
checked on Oct 5, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.